REGN

Regeneron Pharmaceuticals
D

REGN

808.56
USD
24.46
(3.12%)
مغلق
حجم التداول
28,533
الربح لكل سهم
46
العائد الربحي
0.46
P/E
20
حجم السوق
83,245,285,097
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Regeneron Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.